NASDAQ:SYRE Spyre Therapeutics Q3 2024 Earnings Report $93.14 +1.11 (+1.20%) As of 10:09 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Spyre Therapeutics EPS ResultsActual EPS-$1.36Consensus EPS -$0.80Beat/MissMissed by -$0.56One Year Ago EPSN/ASpyre Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASpyre Therapeutics Announcement DetailsQuarterQ3 2024Date11/7/2024TimeAfter Market ClosesConference Call DateThursday, November 7, 2024Conference Call Time4:00PM ETUpcoming EarningsSpyre Therapeutics' Q3 2026 earnings is estimated for Tuesday, November 3, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Spyre Therapeutics Earnings HeadlinesSpyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Rating of "Moderate Buy" by BrokeragesSeptember 20 at 3:15 AM | americanbankingnews.comSpyre (SYRE) Clears Monotherapy Phase for IBD Portfolio, Setting Up Combination TestsSeptember 17, 2026 | finance.yahoo.comIran War WARNING: Something Just ChangedA powerful Middle Eastern government is reportedly asking Trump for U.S. military help against Iran backed forces. One writer says the request echoes a secret January meeting outside Washington, D.C., where an anonymous source described American military protection as part of something much bigger, involving Trump, Iran, and potentially trillions of dollars.September 22 at 1:00 AM | Banyan Hill Publishing (Ad)Financial Contrast: Spyre Therapeutics (NASDAQ:SYRE) vs. Genmab A/S (NASDAQ:GMAB)September 17, 2026 | americanbankingnews.comSpyre Therapeutics (NASDAQ:SYRE) Earns Outperform Rating from WedbushSeptember 11, 2026 | americanbankingnews.comSpyre Therapeutics (SYRE) Reports SPY003 Endoscopic Improvement. Can Randomized Testing Confirm It?September 10, 2026 | insidermonkey.comSee More Spyre Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Spyre Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Spyre Therapeutics and other key companies, straight to your email. Email Address About Spyre TherapeuticsSpyre Therapeutics (NASDAQ:SYRE) is a clinical-stage biotechnology company focused on developing next-generation antibody therapies for inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis. The company’s approach is designed to address significant treatment needs in chronic immune-mediated conditions through therapies with potentially improved efficacy, durability and dosing convenience. Spyre’s pipeline includes investigational antibody programs targeting biological pathways associated with IBD, including interleukin-23 (IL-23), TL1A and integrin-mediated immune activity. Its development strategy combines these targeted medicines with biomarker-driven research and combination approaches intended to improve disease control and patient outcomes. The company’s product candidates remain investigational and are subject to clinical testing and regulatory review. Spyre was created through the combination of private Spyre Therapeutics and Aeglea BioTherapeutics, with the transaction resulting in the public company’s current name and Nasdaq listing under the symbol SYRE. The company is headquartered in the United States and conducts research and clinical-development activities for its IBD programs, including through clinical studies that may involve patients and research sites in multiple geographies.View Spyre Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Nucor and Steel Dynamics Just Pulled Back—The Steel Story Still Looks Strong5 Dividend Stocks That Combine Income, Earnings Growth, and Wall Street SupportDespite Record Sales, Texas Roadhouse Has Beef With Beef CostsEncore Capital Group Has Doubled—But Its Best Tailwind Won’t Last ForeverCoach’s Momentum Powers Tapestry Despite the Stock’s Sharp Pullback3 Retail Stocks Getting Crushed and the Long-Dated Options Trade on Each One3 Surging Stocks That Don’t Need the AI Boom to Keep Winning Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
